Rogelio Silva, MD
Gastroenterology · Oak Lawn, ILNPI 1962493064
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $336,575 of the $402,442 with a category attached, or 83.6%. AbbVie accounts for 96.3% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $102,550 and has fallen 62.0% since, to $39,016 in 2025. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 666 payments — averaging $604.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$388K
- Covidien LP$5K
- Madrigal Pharmaceuticals$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Redhill Biopharma Inc.$2K
- Medtronic$679
- plus $2K from 20 others
What the payments were for
- Consulting fees$16,4454%
- Speaking & faculty fees$336,57584%
- Travel & lodging$36,4389%
- Food & beverage$12,9483%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 395 | $387,679 |
| Covidien LP | 4 | $5,263 |
| Madrigal Pharmaceuticals | 7 | $3,046 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 156 | $1,835 |
| Redhill Biopharma Inc. | 2 | $1,684 |
| Medtronic | 7 | $679 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $451 |
| E.r. Squibb & Sons, L.L.C. | 3 | $341 |
| Johnson & Johnson | 12 | $258 |
| QOL Medical, LLC | 11 | $257 |
| Pfizer | 9 | $186 |
| Bristol Myers Squibb | 8 | $170 |
| Evoke Pharma, Inc. | 5 | $109 |
| Merck | 1 | $92 |
| Ardelyx, Inc. | 3 | $85 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Vivus LLC | 2 | $44 |
| Micro-tech Endoscopy USA, Inc. | 3 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Lilly USA, LLC | 1 | $28 |
| Boston Scientific | 1 | $27 |
| Shionogi Inc | 1 | $26 |
| Capsovision, Inc. | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$402,442 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 15 | $371,762 |
| CreonLipase/Protease/Amylase | 84 | $285,923 |
| LinzessLinaclotide | 62 | $41,144 |
| XifaxanRifaximin | 12 | $36,025 |
| TrulancePlecanatide | 27 | $33,871 |
| Mesalamine | 67 | $30,179 |
| Budesonide ErBudesonide | 14 | $10,714 |
| MotegrityPrucalopride Succinate | 13 | $9,205 |
| Pantoprazole Sodium | 421 | $3,916 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 161 | $3,151 |
| Lubiprostone | 18 | $2,514 |
| Mesalamine ErMesalamine | 20 | $2,369 |
| Lactulose | 22 | $2,096 |
| Sucralfate | 51 | $1,629 |
| CholestyramineCholestyramine (With Sugar) | 26 | $1,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $258 | $371,76215 claims |
| AbbVieCreon, Linzess | $387,679 | $327,067146 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,835 | $69,89639 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $451 | $9,20513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Oak Lawn
- Kamran AyubOak Lawn$266K
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Amar NaikDes Plaines$1.2M
- Darren BrennerChicago$1.1M
- Jonathan RosenbergGurnee$1M
- Daksesh PatelEvanston$745K
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.